Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions

Overview

Journal Chem Res Toxicol

Publisher American Chemical Society

Specialty Toxicology

Date 2016 Jul 30

PMID 27472660

Citations 38

Authors

F Peter Guengerich

Affiliations

Soon will be listed here.

Abstract

Today much is known about cytochrome P450 (P450) enzymes and their catalytic specificity, but the range of reactions catalyzed by each still continues to surprise. Historically, P450s had been considered to be involved in either the metabolism of xenobiotics or endogenous chemicals, in the former case playing a generally protective role and in the latter case a defined physiological role. However, the line of demarcation is sometimes blurred. It is difficult to be completely specific in drug design, and some P450s involved in the metabolism of steroids and vitamins can be off-targets. In a number of cases, drugs have been developed that act on some of those P450s as primary targets, e.g., steroid aromatase inhibitors. Several of the P450s involved in the metabolism of endogenous substrates are less specific than once thought and oxidize several related structures. Some of the P450s that primarily oxidize endogenous chemicals have been shown to oxidize xenobiotic chemicals, even in a bioactivation mode.

Citing Articles

Characterization and Proteomic Profiling of Hepatocyte-like Cells Derived from Human Wharton's Jelly Mesenchymal Stromal Cells: De Novo Expression of Liver-Specific Enzymes.

Lo Iacono M, Corrao S, Alberti G, Amico G, Timoneri F, Russo E Biology (Basel). 2025; 14(2).

PMID: 40001892 PMC: 11851833. DOI: 10.3390/biology14020124.

SNPs in cytochromes P450 catalyzing cholesterol degradation in brain are associated with Parkinson's disease.

Petkova-Kirova P, Kolchina A, Baas S, Wagenpfeil G, Unger M, Schulze-Hentrich J Front Pharmacol. 2024; 15:1477009.

PMID: 39403150 PMC: 11472000. DOI: 10.3389/fphar.2024.1477009.

Engineering Electron Transfer Pathway of Cytochrome P450s.

He J, Liu X, Li C Molecules. 2024; 29(11).

PMID: 38893355 PMC: 11173547. DOI: 10.3390/molecules29112480.

Alteration of Hepatic Cytochrome P450 Expression and Arachidonic Acid Metabolism by Arsenic Trioxide (ATO) in C57BL/6 Mice.

El-Ghiaty M, Alqahtani M, El-Mahrouk S, Isse F, Alammari A, El-Kadi A Biol Trace Elem Res. 2024; 203(2):1000-1015.

PMID: 38758479 DOI: 10.1007/s12011-024-04225-1.

Bielectrode Strategy for Determination of CYP2E1 Catalytic Activity: Electrodes with Bactosomes and Voltammetric Determination of 6-Hydroxychlorzoxazone.

Kuzikov A, Masamrekh R, Filippova T, Tumilovich A, Strushkevich N, Gilep A Biomedicines. 2024; 12(1).

PMID: 38255257 PMC: 10812958. DOI: 10.3390/biomedicines12010152.

References

Hecht S, Kassie F, Hatsukami D . Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer. 2009; 9(7):476-88. PMC: 3876956. DOI: 10.1038/nrc2674. View

Endicott J, Ling V . The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989; 58:137-71. DOI: 10.1146/annurev.bi.58.070189.001033. View

Wacher V, Wu C, Benet L . Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995; 13(3):129-34. DOI: 10.1002/mc.2940130302. View

Cummins C, Jacobsen W, Benet L . Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002; 300(3):1036-45. DOI: 10.1124/jpet.300.3.1036. View

Fu X, Latendresse J, Muskhelishvili L, Blaydes B, Delclos K . Dietary modulation of 7,12-dimethylbenz[a]anthracene (DMBA)-induced adrenal toxicity in female Sprague-Dawley rats. Food Chem Toxicol. 2005; 43(5):765-74. DOI: 10.1016/j.fct.2005.01.017. View

Temple T, LIDDLE G . Inhibitors of adrenal steroid biosynthesis. Annu Rev Pharmacol. 1970; 10:199-218. DOI: 10.1146/annurev.pa.10.040170.001215. View

Thummel K, Wilkinson G . In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998; 38:389-430. DOI: 10.1146/annurev.pharmtox.38.1.389. View

Krauser J, Voehler M, Tseng L, Schefer A, Godejohann M, Guengerich F . Testosterone 1 beta-hydroxylation by human cytochrome P450 3A4. Eur J Biochem. 2004; 271(19):3962-9. DOI: 10.1111/j.1432-1033.2004.04339.x. View

von Weymarn L, Chun J, Hollenberg P . Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers. Carcinogenesis. 2005; 27(4):782-90. DOI: 10.1093/carcin/bgi301. View

10.

Shinkyo R, Xu L, Tallman K, Cheng Q, Porter N, Guengerich F . Conversion of 7-dehydrocholesterol to 7-ketocholesterol is catalyzed by human cytochrome P450 7A1 and occurs by direct oxidation without an epoxide intermediate. J Biol Chem. 2011; 286(38):33021-8. PMC: 3190903. DOI: 10.1074/jbc.M111.282434. View

11.

Mast N, Charvet C, Pikuleva I, Stout C . Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain. J Biol Chem. 2010; 285(41):31783-95. PMC: 2951250. DOI: 10.1074/jbc.M110.143313. View

12.

Johansson M, Larsson C, Bergman A, Lund B . Structure-activity relationship for inhibition of CYP11B1-dependent glucocorticoid synthesis in Y1 cells by aryl methyl sulfones. Pharmacol Toxicol. 1998; 83(5):225-30. DOI: 10.1111/j.1600-0773.1998.tb01473.x. View

13.

Goyal S, Xiao Y, Porter N, Xu L, Guengerich F . Oxidation of 7-dehydrocholesterol and desmosterol by human cytochrome P450 46A1. J Lipid Res. 2014; 55(9):1933-43. PMC: 4617353. DOI: 10.1194/jlr.M051508. View

14.

Chun Y, Kim S, Kim D, Lee S, Guengerich F . A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 2001; 61(22):8164-70. View

15.

Lindhe O, Lund B, Bergman A, Brandt I . Irreversible binding and adrenocorticolytic activity of the DDT metabolite 3-methylsulfonyl-DDE examined in tissue-slice culture. Environ Health Perspect. 2001; 109(2):105-10. PMC: 1240628. DOI: 10.1289/ehp.109-1240628. View

16.

MARTZ F, Straw J . Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metab Dispos. 1980; 8(3):127-30. View

17.

Shinkyo R, Guengerich F . Inhibition of human cytochrome P450 3A4 by cholesterol. J Biol Chem. 2011; 286(21):18426-33. PMC: 3099659. DOI: 10.1074/jbc.M111.240457. View

18.

DeVore N, Scott E . Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature. 2012; 482(7383):116-9. PMC: 3271139. DOI: 10.1038/nature10743. View

19.

Mast N, Li Y, Linger M, Clark M, Wiseman J, Pikuleva I . Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice. J Biol Chem. 2013; 289(6):3529-38. PMC: 3916554. DOI: 10.1074/jbc.M113.532846. View

20.

Stoilov I, Akarsu A, Sarfarazi M . Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet. 1997; 6(4):641-7. DOI: 10.1093/hmg/6.4.641. View